Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Jul 31, 2026
SQQQ's $60 Target: Evaluating the Potential +50% Upside from Recent Levels

SQQQ's $60 Target: Evaluating the Potential +50% Upside from Recent Levels

Key Takeaways

  • Price target: $60 represents a roughly 50% upside from SQQQ's recent trading range near $40 and coincides with a key psychological and technical zone.
  • Bullish catalyst: A meaningful Nasdaq-100 correction of 15–20% could propel SQQQ toward the $60 level, given the ETF's -3x daily leveraged inverse structure.
  • Key obstacle: The persistent long-term uptrend in technology equities and the structural decay inherent in leveraged ETFs make sustained rallies in SQQQ exceptionally difficult to maintain.
  • Critical resistance: The 50-day moving average near $44 and the 200-day moving average around $62 serve as major technical barriers on any upward move.
  • Bottom line: While $60 is achievable during a sharp Nasdaq pullback, holding that level requires a sustained market downturn—something that has repeatedly eluded bearish positions over the past several years.

Why the $60 Level Draws Attention

The $60 price target for the ProShares UltraPro Short QQQ ETF (SQQQ) has become a focal point among traders tracking the technology-heavy Nasdaq-100 for signs of weakness. SQQQ is a -3x daily leveraged inverse ETF, meaning it seeks to deliver three times the opposite of the Nasdaq-100's daily percentage move. When the Nasdaq-100 falls 1%, SQQQ is designed to rise approximately 3%—and when the index rallies, SQQQ falls three times as fast.

With SQQQ trading near $40 in late July 2026 and a 52-week range spanning from $35.80 to $98.85, the $60 target sits roughly midway between the recent trough and the prior peak. It represents a level where bearish conviction would need to intensify considerably, translating into a roughly 15–20% correction in the underlying Nasdaq-100 index depending on the path and duration of the decline.

The Mechanics Behind SQQQ's Leveraged Structure

Before evaluating whether $60 is realistic, investors must understand what SQQQ actually holds. Rather than owning shares of individual companies, SQQQ uses derivatives—primarily swap agreements and futures contracts—to achieve its -3x daily objective. The fund's largest exposures mirror the Nasdaq-100's top constituents in reverse: when mega-cap names like Apple, Microsoft, Nvidia, Amazon, Alphabet, Meta Platforms, and Tesla decline, SQQQ benefits disproportionately.

This structure also introduces daily compounding effects. Over periods longer than a single trading session, SQQQ's returns can deviate significantly from a simple -3x multiple of the Nasdaq-100's cumulative return. In trending markets—either up or down—this compounding can work in the holder's favor. In choppy, range-bound markets, however, the constant resetting of daily leverage erodes value through a phenomenon known as volatility decay. Over the past three years, SQQQ has declined roughly 89%, even though the Nasdaq-100 experienced periods of drawdown during that span. I also checked comparable patterns using Tickeron’s AI Pattern Search Engine to see how similar setups have played out historically.

Potential Catalysts for a Move to $60

Several macro conditions could trigger the kind of Nasdaq-100 selloff necessary to push SQQQ toward $60. A resurgence of inflation forcing the Federal Reserve to maintain or raise interest rates would pressure the growth-oriented technology stocks that dominate the Nasdaq-100. High valuations among the index's largest constituents—many trading at elevated price-to-earnings multiples—leave them vulnerable to multiple compression if earnings disappoint or bond yields climb.

Geopolitical tensions, trade policy disruptions, or a deterioration in corporate earnings growth could also catalyze a rotation out of risk assets. Technology stocks have benefited enormously from artificial intelligence enthusiasm, but any slowdown in AI-related capital expenditure or monetization progress could puncture that narrative. A 15–20% Nasdaq-100 correction from recent levels would, in a relatively smooth decline, translate to SQQQ approaching or breaching the $60 threshold.

Barriers to Reaching and Holding $60

The most formidable headwind facing SQQQ is the multi-year structural uptrend in U.S. equities, particularly in technology. The Nasdaq-100 has proven remarkably resilient, supported by consistent earnings outperformance from mega-cap technology companies, share buyback programs, and persistent investor appetite for growth exposure. Even during periods of elevated volatility, dip-buying has historically overwhelmed selling pressure before bearish positions could fully capitalize.

Additionally, SQQQ carries a 0.95% net expense ratio and experiences the compounding decay discussed earlier. Holding the ETF for weeks or months while waiting for a correction erodes capital even if the Nasdaq-100 moves sideways. The fund's total net assets of approximately $2 billion reflect its role primarily as a tactical hedging or short-term trading instrument rather than a buy-and-hold investment.

Key Technical Levels to Watch

From a technical analysis standpoint, SQQQ faces immediate resistance near the $44 level, which aligns with the 50-day simple moving average. A decisive break above that zone would signal strengthening bearish momentum in the underlying index. Further overhead, the 200-day moving average near $62 forms a major structural barrier—remarkably close to the $60 target. This convergence of a psychological round number with a widely followed long-term moving average makes the $60–$62 zone a significant supply area where sellers may emerge aggressively.

On the downside, support near $36–$38 has held multiple times in recent months, marking the lower boundary of SQQQ's current range. A breakdown below that floor would invalidate the bullish case and likely coincide with new highs in the Nasdaq-100. From what I see in the charts, these levels remain critical markers.

Historical Performance and Sentiment

SQQQ's long-term price history tells a stark story about the difficulty of betting against the Nasdaq-100. The ETF has undergone multiple reverse stock splits since its 2010 inception to maintain a tradeable share price, reflecting the cumulative erosion caused by rising equity markets. The fund's 52-week high of $98.85 was reached during a period of pronounced Nasdaq weakness in mid-2025, demonstrating how rapidly SQQQ can spike when conditions align—but also how fleeting those spikes tend to be.

Current market sentiment, as reflected in options positioning and fund flows, continues to lean bullish on technology. Any shift toward sustained bearishness would likely need to be preceded by a deterioration in forward earnings guidance from the mega-cap leadership group or a clear macroeconomic catalyst.

AI Daily Buy/Sell Signals

In my own analysis of volatile instruments like SQQQ, I turn to Tickeron’s AI Daily Buy/Sell Signals to generate timely, data-driven insights. The system continuously monitors thousands of stocks and ETFs, including leveraged and inverse products, producing Buy, Sell, or Hold signals based on technical patterns, trend strength, and AI models. This helps me identify emerging opportunities and manage positions with greater discipline in fast-moving markets.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SQQQ

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


SQQQ's Stochastic Oscillator sits in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for SQQQ crossed bullishly above the 50-day moving average on July 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SQQQ advanced for three days, in of 255 cases, the price rose further within the following month. The odds of a continued upward trend are .

SQQQ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 140 cases where SQQQ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for SQQQ moved out of overbought territory on July 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on August 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SQQQ as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SQQQ turned negative on August 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

SQQQ moved below its 50-day moving average on August 04, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SQQQ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Industry description

The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the NASDAQ-100 Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index includes 100 of the largest domestic and international non-financial companies listed on The Nasdaq Stock Market based on market capitalization. The fund is non-diversified.
View a ticker or compare two or three
SQQQ
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Inverse Equity
Address
ProShares Trust7501 Wisconsin Avenue,Suite 1000Bethesda
Phone
N/A
Web
www.proshares.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
SQQQ's $60 Target: Evaluating the Potential +50% Upside from Recent Levels